ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.59 and traded as high as $6.72. ImmuCell shares last traded at $6.62, with a volume of 2,570 shares trading hands.
ImmuCell Trading Up 0.3%
The firm has a market cap of $59.84 million, a PE ratio of -94.56 and a beta of 0.32. The company's fifty day moving average price is $6.35 and its two-hundred day moving average price is $5.59. The company has a quick ratio of 2.21, a current ratio of 4.12 and a debt-to-equity ratio of 0.30.
ImmuCell (NASDAQ:ICCC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. ImmuCell had a negative net margin of 1.00% and a negative return on equity of 1.02%. The firm had revenue of $8.07 million during the quarter.
Institutional Trading of ImmuCell
Large investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of ImmuCell during the fourth quarter worth approximately $149,000. Northern Trust Corp grew its stake in ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after buying an additional 14,982 shares during the last quarter. Geode Capital Management LLC increased its position in ImmuCell by 13.9% during the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock worth $332,000 after acquiring an additional 7,878 shares during the period. Finally, Dauntless Investment Group LLC bought a new stake in ImmuCell in the 4th quarter valued at $676,000. Institutional investors and hedge funds own 13.47% of the company's stock.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
See Also
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
